Search filters

List of works by Farrukh T Awan

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

scientific article

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

scientific article published on 7 December 2015

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

scientific article published on 01 May 2019

An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia

scientific article published on 14 September 2020

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib

scientific article published on 01 February 2019

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

scientific article published on 13 February 2017

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody

scientific article

Choosing ibrutinib wisely

scientific article

Cure for CLL?

scientific article

Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia

scientific article published on 21 September 2020

Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

scientific article published on 11 January 2019

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

scientific article published in April 2015

Ibrutinib treatment improves T cell number and function in CLL patients

scientific article published on 17 July 2017

Ibrutinib: targeting the hidden CLL.

scientific article

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

scientific article

Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia

scientific article published on 19 November 2020

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients

scientific article

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

scientific article published on 15 August 2018

Paulina is supported by:

About Paulina

Help